

LITERATURA

1. Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. *Ann Neurol.* 2001;49:512-517.
2. Blevins LS, Jr., Shankroff J, Moser HW, et al. Elevated plasma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuropathy. *J Clin Endocrinol Metab.* 1994;78:261-265.
3. Di Rocco M, Doria-Lamba L, Caruso U. Monozygotic twins with X-linked adrenoleukodystrophy and different phenotypes. *Ann Neurol.* 2001;50:424.
4. Dubey P, Raymond GV, Moser AB, et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. *J Pediatr.* 2005;146:528-532.
5. Dvorakova L, Hrebicek M, Jahnova H, et al. X-linked adrenoleukodystrophy in twenty one Czech patients. *Ces-slov Pediatr.* 2006;61(3):129-136.
6. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. *N Engl J Med.* 2017;377:1630-1638.
7. Engelen M, Barbier M, Dijkstra IM, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. *Brain.* 2014;137:693-706.
8. Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. *Orphanet J Rare, Dis.* 2012;7:51
9. Engelen M, Ofman R, Dijkgraaf MG, et al. Lovastatin in X-linked adrenoleukodystrophy. *N Engl J Med.* 2010;362:276-277.
10. Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. *Neurology.* 2022;99:940-951.
11. Fanen P, Guidoux S, Sarde CO, et al. Identification of mutations in the putative ATP-binding domain of the adrenoleukodystrophy gene. *J Clin Invest.* 1994;94:516-520.
12. Fatemi A, Barker PB, Ulug AM, et al. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy. *Neurology.* 2003;60:1301-1307
13. Fourcade S, Lopez-Erasquin J, Galino J, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. *Hum Mol Genet.* 2008;17:1762-1773.
14. Guettches AK, Kuechler A, Gal A, et al. Female carriers of X-chromosomal adrenoleukodystrophy: a major differential diagnosis in progressive myelopathy. *J Neurol.* 2010;257:1394-1395.
15. Hershkovitz E, Narkis G, Shorer Z, et al. Cerebral X-linked adrenoleukodystrophy in a girl with Xq27-Ter deletion. *Ann Neurol.* 2002;52:234-237.
16. Huffnagel IC, Dijkgraaf MGW, Janssens GE, et al. Disease progression in women with X-linked adrenoleukodystrophy is slow. *Orphanet J Rare, Dis.* 2019;14:30.
17. Huffnagel IC, Laheji FK, Aziz-Bose R, et al. The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. *J Clin Endocrinol Metab.* 2019;104:118-126.
18. Huffnagel IC, van de Beek MC, Showers AL, et al. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. *Mol Genet Metab.* 2017;122:209-215.
19. Jaspers YR, Ferdinandusse S, Dijkstra IM, et al. Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders. *Front Cell Dev Biol.* 2020;8:690.
20. Keam SJ. Elivaldogene Autotemcel: First Approval. *Mol Diagn Ther.* 2021;25:803-809.
21. Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. *Biochim Biophys Acta.* 2012;1822:1465-1474.
22. Kemp S, Huffnagel IC, Linthorst GE, et al. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. *Nat Rev Endocrinol.* 2016;12:606-615.
23. Kemp S, Pujol A, Waterham HR, et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. *Hum Mutat.* 2001;18:499-515.
24. Korenke GC, Fuchs S, Krasemann E, et al. Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. *Ann Neurol.* 1996;40:254-257.
25. Krasemann EW, Meier V, Korenke GC, et al. Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy. *Hum Genet.* 1996;97:194-197.
26. Lauer A, Da X, Hansen MB, et al. ABCD1 dysfunction alters white matter microvascular perfusion. *Brain.* 2017;140:3139-3152.
27. Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. *AJNR Am J Neuroradiol.* 1994;15:1761-1766.
28. Mahmood A, Dubey P, Moser HW, et al. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. *Pediatr Transplant.* 2005;9(Suppl. 7):55-62.
29. Mahmood A, Raymond GV, Dubey P, et al. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. *Lancet Neurol.* 2007;6:687-692.
30. Monternier PA, Singh J, Parasar P, et al. Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy. *J Inherit Metab, Dis.* 2022;45:832-847.
31. Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. *Ann Neurol.* 1999;45:100-110.
32. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. *Nat Clin Pract Neurol.* 2007;3:140-151.
33. Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. *JAMA.* 2005;294:3131-3134.
34. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. *Blood.* 2011;118:1971-1978.
35. Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. *Blood.* 2004;104:881-888.
36. Powers JM, Liu Y, Moser AB, et al. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. *J Neuropathol Exp Neurol.* 1992;51:630-643.
37. Powers JM, Schaumburg HH. Adreno-leukodystrophy. Similar ultrastructural changes in adrenal cortical and Schwann cells. *Arch Neurol.* 1974;30:406-408.
38. Raymond GV, Aubourg P, Paker A, et al. Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2019;25:538-548.
39. Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. *Mol Diagn Ther.* 2007;11:381-384.
40. Turk BR, Theda C, Fatemi A, et al. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. *Int J Dev Neurosci.* 2020;80:52-72.
41. van de Stadt SIW, Huffnagel IC, Turk BR, et al. Imaging in X-Linked Adrenoleukodystrophy. *Neuropediatrics.* 2021;52:252-260.
42. van Geel BM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. *Ann Neurol.* 2001;49:186-194.
43. van Geel BM, Koelman JH, Barth PG, et al. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. *Neurology.* 1996; 46: 112-118
44. Wanders RJ. Metabolic functions of peroxisomes in health and disease. *Biochimie.* 2014;98:36-44.
45. Wang Y, Busin R, Reeves C, et al. X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism. *Mol Genet Metab.* 2011;104:160-166.
46. Zemanova M, Chrastina P, Dvorakova L, et al. X-linked adrenoleukodystrophy: phenotype-genotype correlation in hemizygous males and heterozygous females with ABCD1 mutations. *Neuro Endocrinol Lett.* 2021;42:359-367.
47. Zolman BK, Silva ID, Bartel B. The Arabidopsis pxa1 mutant is defective in an ATP-binding cassette transporter-like protein required for peroxisomal fatty acid beta-oxidation. *Plant Physiol.* 2001;127:1266-1278.

KNÍŽNÍ NOVINKA



**PACIENT A ZDRAVOTNICKÝ PRACOVNÍK
ŘEŠENÍ KONFLIKTNÍCH SITUACÍ**

Auzká Erika

Kniha se zabývá problematikou jednání zdravotnických pracovníků vůči pacientům a jejich rodinným příslušníkům. Na příkladech se autorka snaží přiblížit situace, které běžně ve zdravotnictví nastávají a komplikují pacientům život či dokonce mohou pacienta poškodit. Závěrem každého případu je poučení pro čtenáře, jak by měli ideálně v obdobných situacích jednat.

Autorka vychází ze svých zkušeností dlouholetého pracovníka ve zdravotnictví a ze zkušeností, kterých nabyla v životě jako pacientka či rodinný příslušník pacienta. Zároveň čtenářům přibližuje některá témata související s činností zdravotnických zařízení, o kterých se zpravidla zásadně veřejně nehovoří. Ačkoliv je většina kapitol smutným obrazem českého zdravotnictví, má kniha za cíl povzbudit čtenáře, že svým aktivním postojem dokážou lépe čelit všemu, co může v jejich životech při komunikaci se zdravotníky nastat.